My initial decision to invest was at IPO as I had insight into the effect the RippleDown software had on a pathology labs staffing requirements.

Essentially RippleDown is a sticky solution as part of the overall automation of a pathology lab, reducing staff numbers in the lab even with increasing volumes.

The aqusition of Pavillion Health was the boost the business needed to grow, allowing PKS growth in healthcare outside of just pathology.

Experienced management additions over the past year provide optimism for future growth.

My expectation is the PKS and Pavillion names will be phased out and replaced with Beamtree as was approved this week.